Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mesembrine is a naturally occurring alkaloid primarily found in the plant Sceletium tortuosum (Kanna), native to South Africa[1][2][7]. It features a tricyclic aryloctahydroindole skeleton and is most concentrated in the aerial parts of the plant[7]. Mesembrine is best known for its potent inhibition of the serotonin transporter (SERT), acting as a serotonin reuptake inhibitor (SRI) with greater potency than fluoxetine[3][5][7]. Additionally, it inhibits the enzyme phosphodiesterase-4 (PDE4), which increases intracellular cAMP and may contribute to its antidepressant, anxiolytic, and possible cognitive-enhancing effects[1][3]. Mesembrine-containing extracts have been traditionally used for managing symptoms of anxiety, depression, stress, and for mood elevation[1][3][7]. Other potential indications under investigation include reduction of substance cravings and amelioration of withdrawal symptoms[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mesembrine.